EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC) 5-Year Yield-on-Cost %: 47.57 (As of Jul. 07, 2026)— 17% Below Median
IST:ECILC's 5-Year Yield-on-Cost % is ranked better than 97.88% of 518
companies
in the Drug Manufacturers industry
Industry Median: 2.265
vs IST:ECILC: 47.57
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS 5-Year Yield-on-Cost % Related Terms
IST:ECILC vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC) has a 5-Year Yield-on-Cost % of 47.57 as of Jul. 07, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS and its competitors. This is 17% below median its historical median of 57.37. Over the past decade, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's 5-Year Yield-on-Cost % has ranged from 14.60 to 314.19. According to the industry distribution chart, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS ranks #11 out of 518 companies in the Drug Manufacturers industry, placing it in the top 2.1%.
Is EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's 5-Year Yield-on-Cost % too high?
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's current 5-Year Yield-on-Cost % of 47.57 is 17% below median its 10-year median of 57.37. Over the past 10 years, this metric has ranged from a low of 14.60 to a high of 314.19. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.27. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's value of 47.57 is 2000.2% above this industry median. Based on the distribution chart, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS ranks #11 out of 518 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS ranks #11 out of 518 companies for 5-Year Yield-on-Cost %. This places EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS in the top 2% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.27. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's value of 47.57 is 2000.2% above this benchmark. Historically, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's own 5-Year Yield-on-Cost % has ranged from 14.60 to 314.19 over the past decade. While the company's 10-year median is 57.37 vs. the industry median of 2.27, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.27, based on 518 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's current 5-Year Yield-on-Cost % of 47.57 is 2000.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's current 5-Year Yield-on-Cost % is 47.57, which is 17% below median its own 10-year median of 57.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC) is currently considered Modestly Overvalued. The stock's GF Value™ is ₺60.70, compared to a current price of ₺74.65 — trading 23% above its estimated fair value. The current 5-Year Yield-on-Cost % is 47.57, which is 17% below median its 10-year median of 57.37 and 2000.2% above the Drug Manufacturers industry median of 2.27. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC), the current 5-Year Yield-on-Cost % is 47.57 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC) Overvalued in 2026?
Based on GuruFocus' analysis, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS stock appears to be overvalued.
The current stock price of ₺74.65 is trading 23% above its estimated GF Value™ of ₺60.70.
GuruFocus considers EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS to be Modestly Overvalued.
Key valuation signals for IST:ECILC:
5-Year Yield-on-Cost %: 47.57 (17% below median its 10-year median of 57.37)
GF Value™: ₺60.70 vs. price of ₺74.65 (23% above fair value)
Industry Position: 2000.2% above the Drug Manufacturers median (#11 of 518)
No single metric tells the full story. See the IST:ECILC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS Business Description
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS is a Turkey-based company that operates in the drug business. It is mainly involved in the manufacturing of pharmaceuticals, veterinary drugs, and personal care products. Further, the group is also engaged in real estate development and leasing commercial property activities. Geographically, all the activities are carried out through the region of Turkey.
63GF Score
Get the complete analysis for IST:ECILC
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:ECILC has been successfully added to your 